TY - JOUR
T1 - IL-4 and IL-13 receptors
T2 - Roles in immunity and powerful vaccine adjuvants
AU - Ranasinghe, Charani
AU - Trivedi, Shubhanshi
AU - Wijesundara, Danushka K.
AU - Jackson, Ronald J.
N1 - Publisher Copyright:
© 2014 Published by Elsevier Ltd.
PY - 2014/8/1
Y1 - 2014/8/1
N2 - The roles of interleukin (IL)-4 and IL-13 during both innate and adaptive Th2 mediated immunity have received considerable scrutiny, however, mechanisms by which these cytokines influence the cellular interactions involved in negatively modulating the development of effective Th1 immunity are poorly characterized. In this article we discuss the recent advances in IL-4/IL-13 biology, mainly (i) role of these cytokines in allergic inflammation, atopic dermatitis, cancer, transplant rejection, bacterial/viral infections, and specifically the therapeutic potential of IL-13Rα2, (ii) insights into how "alarmin" stimulation activate IL-4/IL-13 at the lung mucosae, (iii) how these two cytokines modulate antigen-specific CD8+ T cell quality/avidity in a vaccine route dependent manner and (iv) finally discuss the potential of using transient inhibition of IL-4 and/or IL-13 at the vaccination site as a platform vaccine technology to induce strong sustained high quality CD8+ T cell immunity for protection against many chronic mucosal pathogens such as HIV-1.
AB - The roles of interleukin (IL)-4 and IL-13 during both innate and adaptive Th2 mediated immunity have received considerable scrutiny, however, mechanisms by which these cytokines influence the cellular interactions involved in negatively modulating the development of effective Th1 immunity are poorly characterized. In this article we discuss the recent advances in IL-4/IL-13 biology, mainly (i) role of these cytokines in allergic inflammation, atopic dermatitis, cancer, transplant rejection, bacterial/viral infections, and specifically the therapeutic potential of IL-13Rα2, (ii) insights into how "alarmin" stimulation activate IL-4/IL-13 at the lung mucosae, (iii) how these two cytokines modulate antigen-specific CD8+ T cell quality/avidity in a vaccine route dependent manner and (iv) finally discuss the potential of using transient inhibition of IL-4 and/or IL-13 at the vaccination site as a platform vaccine technology to induce strong sustained high quality CD8+ T cell immunity for protection against many chronic mucosal pathogens such as HIV-1.
KW - CD8 T cell avidity
KW - IL-13Ra2
KW - IL-4R antagonist
KW - Infection and immunity
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=84907965970&partnerID=8YFLogxK
U2 - 10.1016/j.cytogfr.2014.07.010
DO - 10.1016/j.cytogfr.2014.07.010
M3 - Short survey
SN - 1359-6101
VL - 25
SP - 437
EP - 442
JO - Cytokine and Growth Factor Reviews
JF - Cytokine and Growth Factor Reviews
IS - 4
ER -